Cognition shares jump 10.87% intraday after completing expanded access program enrollment for zervimesine in DLB, funded by family donation.

Cognition Therapeutics (NASDAQ: CGTX) surged 10.87% intraday after announcing full enrollment in its expanded access program for zervimesine (CT1812) in dementia with Lewy bodies (DLB). The program, funded by a donation from a Phase 2 SHIMMER study participant’s family, treats enrolled patients with 100 mg of zervimesine daily for up to one year. CEO Lisa Ricciardi highlighted the rapid enrollment in three months, underscoring strong patient demand and operational efficiency. The company also confirmed a Type C meeting with the FDA in late January to discuss a Phase 3 program design for DLB, aligning with prior regulatory alignment for Alzheimer’s disease. The news reinforced progress in zervimesine’s clinical development and regulatory pathway, driving immediate investor optimism about the drug’s potential and Cognition’s strategic advancements in neurodegenerative disease treatments.